These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 32394767)

  • 1. Glioblastoma multiforme: novel therapeutic targets.
    Muir M; Gopakumar S; Traylor J; Lee S; Rao G
    Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA and extracellular vesicles in glioblastoma: small but powerful.
    Rooj AK; Mineo M; Godlewski J
    Brain Tumor Pathol; 2016 Apr; 33(2):77-88. PubMed ID: 26968172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
    Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies.
    Morisse MC; Jouannet S; Dominguez-Villar M; Sanson M; Idbaih A
    Expert Rev Neurother; 2018 Sep; 18(9):729-737. PubMed ID: 30099909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-angiogenic gene therapy in the treatment of malignant gliomas.
    Gatson NN; Chiocca EA; Kaur B
    Neurosci Lett; 2012 Oct; 527(2):62-70. PubMed ID: 22906922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma.
    Rivera M; Bander ED; Cisse B
    World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
    DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
    Front Immunol; 2020; 11():1402. PubMed ID: 32765498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
    Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
    J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.
    Habib A; Pease M; Kodavali CV; Amankulor N; Zinn PO
    J Neurooncol; 2021 Jan; 151(2):103-112. PubMed ID: 33394264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma.
    Goenka A; Tiek D; Song X; Huang T; Hu B; Cheng SY
    Cells; 2021 Feb; 10(3):. PubMed ID: 33668200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
    Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
    J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma Therapy in the Age of Molecular Medicine.
    Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS
    Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.
    Yu W; Liang S; Zhang C
    Neuromolecular Med; 2018 Dec; 20(4):452-474. PubMed ID: 30182330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
    Anthony C; Mladkova-Suchy N; Adamson DC
    Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
    [No Abstract]   [Full Text] [Related]  

  • 20. Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.
    Arbab AS; Rashid MH; Angara K; Borin TF; Lin PC; Jain M; Achyut BR
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.